摘要
目的探讨不同他汀类药物强化治疗对急性心肌梗死(AMI)患者超敏C反应蛋白(hs CRP)的影响。方法200例AMI患者采用简单随机抽样法分为四组各50例,均按照临床路径予以标准化治疗方案,分别给予阿托伐他汀80 mg/d(A组)、瑞舒伐他汀组20 mg/d(B组)、阿托伐他汀20 mg/d(C组)及瑞舒伐他汀组10 mg/d(D组)治疗。比较各组入院后及服药2周时测定患者血脂及hs-CRP水平。结果治疗后四组hs-CRP、TC、LDL-C水平均较治疗前明显下降,差异有统计学意义(P<0.05),且B组低于A组和D组,差异有统计学意义(P<0.05),A组、C组与D组之间比较,差异均无统计学意义(P>0.05)。结论强化他汀治疗在有效调脂的同时可剂量依赖性显著降低AMI患者hs CRP水平,瑞舒伐他汀对降低hs CRP效果优于阿托伐他汀。
Objective To investigate the effect of different intensive statins therapies on hypersensitive C reactive protein （hsCRP） in patients with acute myocardial infarction（AMI）. Methods Two hundred AMI patients were divided into four groups ac- cording to a simple random sampling method,50 in each group. The patients were treated with standardized treatment protocols according to the clinical path, i. e. atorvastatin 80 mg/d （group A）, rosuvastatin 20 mg/d （group B）, atorvastatin 20 mg/d （group C）and rosu- vastatin 10 mg/d（ group D）, respectively. Blood lipids and hsCRP levels were measured after 2 weeks of hospitalization and treatment. Results In all four groups, serum levels of TC ,LDL-C and hsCRP were significantly decreased after treatment（ P 〈0. 05）. Further, serum hsCRP level in the group B was significantly lower than that in the groups A and D（P 〈 0. 05）and there was a significant difference in serum hsCRP level among groups A, C and D（P 〉 0.05 ）. Conclusion The intensive statins therapy can significantly reduce the hsCRP level at a dose-dependent manner besides effectively regulation of lipid. The effect of rosuvastatin on hsCRP is better than that of atorvastatin.
出处
《实用医院临床杂志》
2015年第5期90-92,共3页
Practical Journal of Clinical Medicine
